ATLANTIC SAPPHIRE ASA financials
ATLANTIC SAPPHIRE ASA
2138007BY85FI48VX666 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | $22.8M | $14.0M |
| Other income | $59.0K | $1.9M |
| Employee benefits expense | $7.2M | $4.1M |
| Depreciation & amortisation | $14.4M | $13.8M |
| Operating profit (EBIT) | -$163.2M | -$126.2M |
| Finance costs | $8.3M | $9.1M |
| Profit before tax | -$167.3M | -$133.8M |
| Income tax expense | $0 | $0 |
| Profit for the year | -$167.3M | -$133.8M |
| Total comprehensive income | -$170.0M | -$133.4M |
| Per share | ||
| Basic EPS | $-17.19 | $-340.39 |
| Diluted EPS | $-17.19 | $-340.39 |
| Free cash flow / share | $-9.91 | $-247.77 |
| Cash flow statement | ||
| Net cash from operating activities | -$87.4M | -$77.8M |
| Net cash from investing activities | -$7.4M | -$33.5M |
| Purchase of PP&E (capex) | $9.1M | $19.6M |
| Net cash from financing activities | $102.9M | $110.3M |
| Proceeds from borrowings | $17.3M | $12.5M |
| Repayments of borrowings | $18.5M | $17.3M |
| Lease liability payments | $455.0K | $468.0K |
| Net change in cash | $8.1M | -$918.0K |
| Balance sheet | ||
| Total assets | $273.7M | $342.3M |
| Non-current assets | $217.0M | $294.6M |
| Property, plant & equipment | $197.7M | $275.6M |
| Right-of-use assets | $1.5M | $2.0M |
| Current assets | $56.7M | $47.7M |
| Inventories | $5.7M | $5.1M |
| Trade & other receivables | $3.7M | $1.2M |
| Cash & equivalents | $29.9M | $23.0M |
| Total equity | $202.8M | $283.1M |
| Non-current liabilities | $63.4M | $39.3M |
| Lease liabilities (non-current) | $1.2M | $1.7M |
| Current liabilities | $7.5M | $19.8M |
| Lease liabilities (current) | $494.0K | $450.0K |
| Trade & other payables | $7.0M | $14.3M |
| Derived metrics | ||
| Free cash flow | -$96.5M | -$97.4M |
| Operating margin | -715.1% | -901.7% |
| Net margin | -733.3% | -955.8% |
| Return on equity | -82.5% | -47.2% |
| Cash conversion ratio | 0.52× | 0.58× |
| Capex coverage | -9.59× | -3.97× |
| Other reported items | ||
| Adjustments For Decrease Increase In Biological Assets | $3.4M | -$12.2M |
| Adjustments For Decrease Increase In Inventories | -$1.7M | -$1.0M |
| Adjustments For Decrease Increase In Other Current Assets | $1.8M | -$1.8M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -$4.5M | $1.6M |
| Adjustments For Depreciation and Amortisation Expense | $14.4M | $13.8M |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | $4.1M | -$14.1M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $73.0M | $35.0M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | $1.2M | $243.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -$7.3M | $2.0M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | $0 | $56.0K |
| Adjustments For Sharebased Payments | $145.0K | -$365.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$1.6M | $558.0K |
| Cash | $29.4M | $22.5M |
| Cost of Merchandise Sold | $83.1M | $67.1M |
| Current Biological Assets | $17.0M | $16.2M |
| Current Loans Received and Current Portion of Noncurrent Loans Received | $0 | $5.0M |
| Current Restricted Cash and Cash Equivalents | $415.0K | $415.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -$1.2M | -$234.0K |
| Equity and Liabilities | $273.7M | $342.3M |
| Finance Income | $4.2M | $1.5M |
| Gains Losses On Fair Value Adjustment Biological Assets | $4.1M | -$14.1M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | $73.0M | $35.0M |
| Interest Paid Classified As Financing Activities | $5.0M | $4.9M |
| Interest Received Classified As Investing Activities | $1.7M | $1.3M |
| Issue of Equity | $89.6M | $120.6M |
| Issued Capital | $38.1M | $8.6M |
| Liabilities | $70.8M | $59.1M |
| Longterm Deposits | $1.6M | $1.4M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | $0 | $6.0K |
| Noncurrent Portion of Noncurrent Loans Received | $41.7M | $37.6M |
| Noncurrent Portion of Noncurrent Notes and Debentures Issued | $20.5M | $0 |
| Noncurrent Receivables | $1.0M | $481.0K |
| Noncurrent Restricted Cash and Cash Equivalents | $15.2M | $15.2M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -$2.7M | $323.0K |
| Other Current Assets | $433.0K | $2.2M |
| Other Inflows Outflows of Cash Classified As Investing Activities | $6.0K | $0 |
| Proceeds From Issue of Bonds Notes and Debentures | $20.0M | $0 |
| Proceeds From Issuing Shares | $89.6M | $120.6M |
| Reserve of Exchange Differences On Translation | -$9.5M | -$6.7M |
| Reserve of Sharebased Payments | $4.1M | $4.0M |
| Retained Earnings | -$581.5M | -$414.2M |
| Selling General and Administrative Expense | $12.4M | $8.0M |
| Share Premium | $751.6M | $691.4M |
Every line item above is a fact tagged in ATLANTIC SAPPHIRE ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.